Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
bacterial infection
cerebrovascular accident
cerebrovascular accident, mimics
chlorpropamide
coma
diabetes mellitus
drug induced neurologic disorders
genetic neurologic disorders
hemiparesis
hypoglycemia
hypoglycemic agent, oral
hypoglycemic coma
iatrogenic neurologic disorders
insulin
level of consciousness, decreased
mimics
mortality
old age, neurology of
optic neuropathy
optic neuropathy, toxic
seizure
tolazamide
transketolase
visual loss
Wernicke's encephalopathy
Showing articles 1400 to 1450 of 4563 << Previous Next >>

Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009

Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009

A 70-Year-Old Woman with Shingles: Review of Herpes Zoster
JAMA 302:73-80,108, Whitley,R.J., 2009

Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009

Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study
Arch Neurol 66:714-720,691, Vernooij,M.W.,et al, 2009

Primary Angiitis of the Central Nervous System
Arch Neurol 66:704-709, Birnbaum,J. &Hellmann,D.B., 2009

Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009

Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009

Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009

Isolated Lateral Sinus Thrombosis: A Series of 62 Patients
Stroke 40:476-481, Damak,M.,et al, 2009

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009

Hemorrhage in Posterior Reversible Encephalopathy Syndrome: Imaging and Clinical Features
AJNR 30:1371-1379, Hefzy,H.M.,et al, 2009

Parkinsonism in HIV-Infected Patients on Highly Active Antiretroviral Therapy
Neurol 73:401-403, Tisch,S. &Brew,B., 2009

Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009

Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009

MR Mismatch Is Useful for Patient Selection for Thrombolysis: Yes
Stroke 40:2906-2907,2910, Fiebach,J.B. &Schellinger,P.D., 2009

4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009

Cerebral Microbleeds Are a Risk Factor for Warfarin-Related Intracerebral Hemorrhage
Neurol 72:171-176, Lee,S.-H.,et al, 2009

Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009

Use of MRI to Estimate the Therapeutic Window in Acute Stroke: Is Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch an EPITHET for Salvageable Ischemic Brain Tissue?
Stroke 40:333-335, Toth,G. &Albers,G.W., 2009

Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009

Acute Limbic Encephalitis and Glutamic Acid Decarboxylase Antibodies:A Reality?
J Neurosci 287:69-71, Blanc,F.,et al, 2009

CNS Complications of Radiotherapy and Chemotherapy
Lancet 374:1639-1651, Soussain,C.,et al, 2009

Migraine and Cardiovascular Disease: Systematic Review and Meta-Analysis
BMJ 339:b3914, Sch�rks,M.,et al, 2009

High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial
Lancet 374:1512-1520, 1477, Ferreri,A.,et al, 2009

Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Neurologic Immune Reconstitution Inflammatory Syndrome in HIV/AIDS: Outcome and Epidemiology
Neurol 72:835-841, McCombe,J.A.,et al, 2009

Cerebral Microbleed Preceding Symptomatic Intracerebral Hemorrhage in a Stroke-Free Person
Neurol 72:763-765, Vernooij,M.W.,et al, 2009

Posterior Reversible Encephalopathy Syndrome in Neuromyelitis Optica Spectrum Disorders
Neurol 72:712-717, Maga�a,S.M.,et al, 2009

Thrombolytic Therapy for Patients Who Wake-Up With Stroke
Stroke 40:827-832, Barreto,A.D.,et al, 2009

Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature
Stroke 40:801-807, Arnold,M.,et al, 2009

Disappearing Hyperdense Middle Cerebral Artery Sign in Ischaemic Stroke Patients Treated with Intravenous Thrombolysis: Clinical Course and Prognostic Significance
JNNP 80:273-278,248, Kharitonova,T.,et al, 2009

Intravascular Lymphoma Masquerading as Multiembolic Stroke Developing After Coronary Artery By-Pass Surgery
The Neurologist 15:98-101, Sumer,M.,et al, 2009

Carbon Monoxide Poisoning
NEJM 360:1217-1225, Weaver,L.K., 2009

Moyamoya Disease and Moyamoya Syndrome
NEJM 360:1226-1237, Scott,R.M. &Smith,E.R., 2009

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009

Stroke in Women: An Evolving Topic
Stroke 40:1027-1028, Kurth,T. &Bousser,M.-G., 2009

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009

Effect of Age on Stroke Prevention Therapy in Patients with Atrial Fibrillation: The Atrial Fibrillation Investigators
Stroke 40:1410-1416, van Walraven,C.,et al, 2009

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009

Cost-Effectiveness of Patient Selection Using Penumbral-Based MRI for Intravenous Thrombolysis
Stroke 40:1710-1720, Earnshaw,S.R.,et al, 2009

Identifying Patients at High Risk for Poor Outcomes After Intra-Arterial Therapy for Acute Ischemic Stroke
Stroke 40:1780-1785, Hallevi,H.,et al, 2009

Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009

Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009



Showing articles 1400 to 1450 of 4563 << Previous Next >>